.svg)
Ozempic and Mounjaro are both injectable medications used in the management of type 2 diabetes, but they work through different mechanisms, contain different active ingredients, and have different clinical profiles. Neither is approved for weight loss as a primary indication, though both produce weight loss as a pharmacological effect. Understanding what actually distinguishes them helps patients and clinicians make better-informed decisions about diabetes management and related treatment goals.
Ozempic vs. Mounjaro: Quick Comparison
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 and GIP receptor agonist |
| FDA-approved indication(s) | Type 2 diabetes mellitus (glycemic control); cardiovascular risk reduction in adults with type 2 diabetes and established CV disease | Type 2 diabetes mellitus (glycemic control) in adults and pediatric patients 10 years and older; cardiovascular risk reduction in adults with type 2 diabetes and established CV disease |
| Approved for weight loss | No (sometimes prescribed off-label) | No (sometimes prescribed off-label) |
| Dosing frequency | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Maintenance dose range | 0.5 mg, 1 mg, or 2 mg weekly | 5 mg, 10 mg, or 15 mg weekly |
| Typical titration duration | ~4-8 weeks to initial maintenance | ~20 weeks to reach 15 mg |
| Common side effects | Nausea, diarrhea, vomiting, constipation, abdominal pain | Nausea, diarrhea, vomiting, constipation, abdominal pain |
| Boxed warning | Thyroid C-cell tumor risk (animal studies; human relevance unknown) | Thyroid C-cell tumor risk (animal studies; human relevance unknown) |
| Key evidence | SUSTAIN trials (glycemic control); PIONEER trials (oral semaglutide); cardiovascular outcomes data | SURPASS trials (glycemic control); SURPASS-CVOT (cardiovascular outcomes) |
| Pediatric approval | No | Yes, ages 10 and older (as of December 2025) |
| Access | Prescription required; generally covered for type 2 diabetes | Prescription required; generally covered for type 2 diabetes |
What Is Ozempic?
Ozempic is a brand name, not an active ingredient. The active ingredient in Ozempic is semaglutide, a GLP-1 receptor agonist that Novo Nordisk developed for the management of type 2 diabetes. Ozempic is distinct from Wegovy, which also contains semaglutide but is approved for weight management at higher doses. Ozempic and Wegovy are not interchangeable despite sharing the same active ingredient.
Ozempic is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It also carries an approved indication for reducing the risk of major cardiovascular events (specifically, cardiovascular death, nonfatal heart attack, and nonfatal stroke) in adults with type 2 diabetes and established cardiovascular disease.
Ozempic is available as a once-weekly subcutaneous injection in maintenance doses of 0.5 mg, 1 mg, and 2 mg. It is not FDA-approved for weight management, and prescribing it for that purpose is considered off-label use.
What Is Mounjaro?
Mounjaro is also a brand name. Its active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist that works through two hormonal pathways simultaneously, distinguishing it mechanistically from Ozempic and every other GLP-1-only medication.
Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults and, as of December 2025, pediatric patients 10 years of age and older with type 2 diabetes. As of August 2026, it also carries an approved indication for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (matching Ozempic's cardiovascular indication in that patient population).
Mounjaro is available as a once-weekly subcutaneous injection starting at 2.5 mg and titrating to maintenance doses of 5 mg, 10 mg, or 15 mg weekly. Like Ozempic, it is not FDA-approved for weight management. Prescribing it for weight loss is off-label. The weight management-approved version of tirzepatide is Zepbound.
How Do Ozempic and Mounjaro Work?
The most clinically meaningful difference between these two medications is the number of receptors each activates, and what those additional receptor activations actually do.
Where they overlap:
Both activate GLP-1 receptors in the brain, pancreas, and stomach, signaling satiety, stimulating glucose-dependent insulin release, suppressing glucagon, and slowing gastric emptying
Both reduce appetite as a consequence of GLP-1 receptor activation, which explains the weight loss both medications produce (even though neither is approved for that indication)
Both improve post-meal blood sugar stability and HbA1c levels
Both share the same thyroid C-cell tumor boxed warning and contraindication for patients with a personal or family history of MTC or MEN2
Both are now approved for cardiovascular risk reduction in adults with type 2 diabetes and established CV disease
Where they differ:
Mounjaro activates GIP (glucose-dependent insulinotropic polypeptide) receptors in addition to GLP-1 receptors. GIP is involved in insulin secretion, energy metabolism, and fat storage. This dual activation appears to produce more pronounced effects on both glycemic control and body weight than GLP-1 activation alone
Ozempic activates GLP-1 receptors only. It has a longer published clinical history and more long-term real-world safety data than tirzepatide
Mounjaro's pediatric approval (patients 10 and older) is an indication Ozempic does not currently share
The dose ranges differ substantially: Ozempic tops out at 2 mg, while Mounjaro reaches 15 mg. Given their different mechanisms and molecular structures, though, these doses are not comparable across the two drugs
How Do Weight Loss Results Compare?
Neither Ozempic nor Mounjaro is approved for weight loss, and the primary endpoints in their clinical trials were glycemic control rather than weight reduction. That said, both can produce clinically meaningful weight loss as a secondary effect.
SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in adults with type 2 diabetes and found greater weight reduction with tirzepatide, although glycemic control, not weight loss, was the primary endpoint. Separately, SURMOUNT-5 directly compared obesity-treatment doses of tirzepatide and semaglutide in adults with obesity without diabetes; those findings apply to the weight-management treatment context rather than directly to Ozempic versus Mounjaro.
| Trial Program | Drug / Dose | Population | Duration | Weight Loss Outcome |
|---|---|---|---|---|
| SUSTAIN 1-7 | Ozempic 0.5-1 mg weekly | Adults with type 2 diabetes | 30-56 weeks | Variable; ~3-6 kg across trials (not primary endpoint) |
| SURPASS-1 | Mounjaro 5-15 mg weekly | Adults with type 2 diabetes (monotherapy) | 40 weeks | ~7-9.5 kg reduction (not primary endpoint) |
| SURPASS-2 | Mounjaro vs. semaglutide 1 mg | Adults with type 2 diabetes | 40 weeks | Greater weight loss with tirzepatide; primary endpoint was HbA1c |
| STEP 2 | Wegovy 2.4 mg weekly | Adults with obesity/overweight and type 2 diabetes | 68 weeks | ~9.6% body weight (weight management dose) |
| SURMOUNT-2 | Zepbound 15 mg weekly | Adults with obesity/overweight and type 2 diabetes | 72 weeks | ~15.7% body weight (weight management dose) |
The SURPASS-2 trial is the most relevant direct comparison. This trial compared tirzepatide to semaglutide 1 mg in the same population and showed greater weight loss with tirzepatide across all doses. However, the semaglutide dose used (1 mg) is lower than Wegovy's weight management dose (2.4 mg), which limits how broadly that finding can be applied. The STEP 2 and SURMOUNT-2 rows illustrate what the weight management-approved doses of each active ingredient can produce in patients with type 2 diabetes, but those are different products at different doses, prescribed for a different indication.
Side Effects and Safety Differences
Both medications produce typical GLP-1 side effects through the same mechanism (slowed gastric emptying) and share the major safety warnings. The practical differences come from dose, mechanism, and patient population.
| Ozempic | Mounjaro | |
|---|---|---|
| Most common GI effects | Nausea, diarrhea, vomiting, constipation (rates vary by dose; generally lower than weight management doses of semaglutide) | Nausea, diarrhea, constipation, vomiting (similar profile; rates vary by dose across SURPASS trials) |
| Severe GI reactions | Severe GI reactions reported postmarketing; October 2025 label update added severe GI adverse reactions warning | Same warning; January 2026 label update added severe GI adverse reactions warning |
| Thyroid C-cell tumor warning | Boxed warning; contraindicated in MTC/MEN2 history | Same boxed warning |
| Pancreatitis | Acute pancreatitis observed; discontinue if suspected | Same warning |
| Gallbladder disease | Cholelithiasis and cholecystitis reported | Same warning |
| Diabetic retinopathy | Worsening of diabetic retinopathy observed with rapid glucose improvement; monitor patients with history | Same monitoring recommendation; particularly relevant given expanded pediatric population |
| Suicidal behavior and ideation | Warning removed from label following FDA review | Warning removed from label following same FDA review |
| Hypoglycemia risk | Low when used alone; higher with insulin or sulfonylureas | Same pattern; sulfonylurea combination in SURMOUNT-2 produced hypoglycemia in ~10.3% vs. ~2.1% without sulfonylurea |
| Oral contraceptive interaction | Injection form; gastric emptying effects may affect oral medication absorption generally | Switch to non-oral contraceptive method or add barrier method for 4 weeks after starting and after each dose increase |
| Pregnancy | Discontinue at least 2 months before planned pregnancy | Discontinue when pregnancy recognized; may cause fetal harm |
| Breastfeeding | Lactation data remain limited. The Ozempic label reports no human milk data. Patients who are breastfeeding should discuss treatment with their clinician. | A single-dose Mounjaro study found tirzepatide levels were undetectable or low in breast milk, but effects on breastfed infants and milk production remain unknown. Patients who are breastfeeding should discuss treatment with their clinician. |
| Pediatric considerations | Not approved for pediatric use | Approved for ages 10+; monitoring considerations apply to younger patients |
One practical difference worth noting: Mounjaro's specific guidance on oral hormonal contraceptives, requiring a switch or barrier method addition, is explicit in its current prescribing label in a way that reflects tirzepatide's pronounced effect on gastric emptying.
Dosing, Administration, and Treatment Experience
Both are once-weekly subcutaneous injections administered in the abdomen, thigh, or upper arm on the same day each week with or without food.
Titration schedules differ significantly. Ozempic starts at 0.25 mg for four weeks, then moves to 0.5 mg as maintenance, with optional increases to 1 mg and then 2 mg based on glycemic response. The escalation can be relatively quick (within weeks rather than months). Mounjaro starts at 2.5 mg and increases in 2.5 mg increments every four weeks through a longer escalation that can take approximately 20 weeks to reach the 15 mg maximum.
Dose ranges are not comparable across medications. Ozempic's maximum approved dose is 2 mg; Mounjaro's is 15 mg. These numbers reflect different molecular structures, mechanisms, and dose-finding processes: not relative potency on a shared scale.
Missed dose windows differ. For Ozempic, take a missed dose as soon as possible within 5 days; if more than 5 days have passed, skip it and take the next dose on the regularly scheduled day. For Mounjaro, take a missed dose within 4 days (96 hours); if more than 4 days have passed, skip it and resume the regular schedule.
Delivery formats. Ozempic is available as a single-patient-use pen delivering 0.25 mg, 0.5 mg, or 1 mg per injection, and a separate pen for 2 mg. Mounjaro is available as a single-dose autoinjector pen, single-dose vial, and single-patient-use KwikPen.
Monitoring considerations. Both require blood glucose monitoring, management of hypoglycemia risk with concomitant medications, and attention to GI tolerability during titration. Mounjaro's pediatric indication introduces additional monitoring considerations for younger patients managing type 2 diabetes.
Cost, Insurance and Availability
Both Ozempic and Mounjaro are prescribed for type 2 diabetes, which means they're more reliably covered by insurance than their weight management counterparts, Wegovy and Zepbound. Prior authorization is still commonly required for both, but approval rates for diabetes indications tend to be higher than for weight management indications.
Without insurance, both medications list at significant prices: over $1,000 per month depending on dose and pharmacy. Manufacturer savings programs from Novo Nordisk (NovoCare) and Eli Lilly can reduce costs for commercially insured patients who qualify, though eligibility restrictions apply and uninsured patients generally don't benefit from these programs.
Medicare Part D covers both for type 2 diabetes. Mounjaro's August 2026 cardiovascular outcomes indication may open additional coverage pathways for eligible patients whose plans recognize that approved use.
Lttl: A More Affordable Alternative for Weight Management
Ozempic and Mounjaro are diabetes medications. However, if weight management is your primary goal rather than glycemic control, the more appropriate clinical path could be a program built around the weight management-approved active ingredients: semaglutide (as in Wegovy) or tirzepatide (as in Zepbound). This determination, of course, should be made by a licensed clinician.
Lttl offers compounded versions of both semaglutide and tirzepatide at significantly lower price points than brand-name products. Compounded semaglutide is currently available through Lttl at $89 per month, all-inclusive. Compounded tirzepatide is currently available at $139 per month, all-inclusive. Both prices cover medication, licensed clinician oversight, unlimited care team access, dose adjustments, and shipping, with no hidden fees.
Compounded semaglutide and tirzepatide are not FDA-approved and have not been independently evaluated by the FDA for safety, efficacy, or quality. Lttl works exclusively with state-licensed 503A compounding pharmacies sourcing active pharmaceutical ingredients from FDA-registered manufacturers, with a Certificate of Analysis included with every shipment.
Which May Be More Appropriate: Ozempic or Mounjaro?
For both medications, the primary clinical context is type 2 diabetes management, and the right choice depends on a patient's complete clinical picture, not on which medication wins a comparison article. A few factors that typically inform your clinician's determination are:
Glycemic control goals. Both medications improve HbA1c, but tirzepatide's dual mechanism produced greater HbA1c reductions across all doses in the SURPASS-2 head-to-head trial. For patients with more challenging glycemic targets, this difference may be clinically relevant.
Weight management as a secondary goal. Both medications produce weight loss as a secondary effect, with tirzepatide generally producing more in the same population. For patients with type 2 diabetes who also have obesity, a clinician may weigh this secondary effect when choosing between the two, though for patients where weight management is the primary goal, Wegovy and Zepbound are the appropriate FDA-approved products.
Cardiovascular history. Both medications now carry approved cardiovascular outcomes indications for adults with type 2 diabetes and established CV disease. The evidence supporting each comes from different trial programs (Ozempic from SUSTAIN-6 and SOUL, Mounjaro from SURPASS-CVOT) and the populations and endpoints differ in ways worth reviewing with a clinician.
Pediatric patients. Mounjaro is approved for type 2 diabetes in patients 10 years and older. Ozempic is not approved for pediatric use. For adolescent patients, this distinction is clinically significant.
Tolerability and titration pace. Mounjaro's longer titration schedule may reduce early GI side effect intensity compared to Ozempic's faster escalation for some patients. Individual tolerance varies considerably for both.
Track record and long-term data. Semaglutide has a longer published clinical history and more accumulated real-world safety data than tirzepatide. For patients or clinicians who place particular weight on established long-term evidence, this may factor into the decision.
Access and coverage. Both are generally covered for type 2 diabetes, but specific formulary status, prior authorization requirements, and out-of-pocket costs vary by plan and can influence which medication is more practical for a given patient.
As with every prescribing decision in this space, the determination belongs with a licensed clinician who has reviewed the patient's full health history, current medications, and clinical goals.
Frequently Asked Questions
Are Ozempic and Mounjaro the Same Medication?
No. Ozempic contains semaglutide and activates GLP-1 receptors only. Mounjaro contains tirzepatide and activates both GLP-1 and GIP receptors. They are different active ingredients, produced by different manufacturers, with different mechanisms and different clinical profiles. Despite both being prescribed for type 2 diabetes, they are not interchangeable.
Which Is Better for Weight Loss, Ozempic or Mounjaro?
Neither is FDA-approved for weight loss. Both are diabetes medications that produce weight loss as a secondary pharmacological effect. In the SURPASS-2 trial, tirzepatide (Mounjaro's active ingredient) produced greater weight loss than semaglutide 1 mg (Ozempic's active ingredient) in adults with type 2 diabetes. However, the semaglutide dose used was lower than the weight management dose in Wegovy. For patients whose primary goal is weight loss, Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide up to 15 mg) are the appropriate FDA-approved options to discuss with a clinician.
Can I Switch From Ozempic to Mounjaro?
Switching between these medications is possible and may make clinical sense: for example, if a patient isn't achieving glycemic or weight goals on Ozempic, or if their clinician determines that tirzepatide's dual mechanism may be more appropriate. The switch should be managed by a licensed clinician and not on your own. This is extremely important, given the different active ingredients, mechanisms, and titration schedules involved. In addition, dose equivalence between the two is not straightforward, and timing of the transition matters.
Is Mounjaro Now Approved for Children?
Yes, as of December 2025. Mounjaro is now approved for type 2 diabetes in pediatric patients 10 years of age and older, in addition to adults. Ozempic does not currently have an approved pediatric indication. For adolescent patients with type 2 diabetes, this makes Mounjaro the clinically appropriate FDA-approved choice between the two.
Can You Use Ozempic or Mounjaro for Weight Loss if You Don't Have Diabetes?
Off-label prescribing of either product for weight management in patients without diabetes is a clinical decision that requires a prescriber's evaluation. The FDA-approved options for weight management without a diabetes indication are Wegovy (semaglutide) and Zepbound (tirzepatide): the weight management-approved formulations of the same active ingredients at higher doses. Patients interested in GLP-1 therapy for weight management should discuss those products with a clinician rather than pursuing off-label use of diabetes-indicated medications.
Bibliography
- Novo Nordisk. (2025). Ozempic (semaglutide) injection, for subcutaneous use: Full prescribing information (Revised October 2025). U.S. Food and Drug Administration. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/42bdd912-2393-44c4-b7e0-47672ca28991/spl-doc?hl=ozempic
- Eli Lilly and Company. (2026). Mounjaro (tirzepatide) injection, for subcutaneous use: Full prescribing information (Revised August 2026). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
- Drucker, D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. https://pubmed.ncbi.nlm.nih.gov/34626851/
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
.svg)
.svg){kind=icon}
